[Manuel_D]

This isn't a de novo principle. It's pretty basic evidence based medicine: if a treatment has negative side effects, there needs to be significant evidence of positive outcomes to justify this treatment.

What "absurd collateral damage" have the UK, Sweden, Denmark, Finland, or Norway encountered when they banned endocrine interventions for treating gender dysphoric youth?

[TimorousBestie]

Talking with you is very difficult when you continue to conflate various claims and stances that are logically distinct.

OP said:

>>> How is it 'disgusting' to try to let someone live as they were born?

Asserting this as an ethical principle leads to absurdities. That’s all that occurred here.

> What "absurd collateral damage" have the UK, Sweden, Denmark, Finland, or Norway encountered when they banned endocrine interventions for treating gender dysphoric youth?

This is irrelevant to the point at hand (nobody here was discussing European medical policy), but this is not accurate. It’s strange, because you’ve correctly summarized what occurred elsewhere.

Let’s go review the situation at https://en.wikipedia.org/wiki/Puberty_blocker

> Danish guidelines published in 2023 recommend the use of puberty blockers on transgender patients at either Tanner stage two or three, as a means of buying time for patients to consider their gender more fully before making a decision.[119]

> In 2020, Finland revised its guidelines to prioritise psychotherapy over medical transition.[120] However, these guidelines are a recommendation, not a mandate.[121][122] The Council for Choices in Health Care allows the use of puberty blockers in transgender children after a case-by-case assessment if there are no medical contraindications.[123][124]

> In 2023, the Norwegian Healthcare Investigation Board, an independent non-governmental organization, issued a non-binding report finding "there is insufficient evidence for the use of puberty blockers and cross sex hormone treatments in young people" and recommending changing to a cautious approach.[148][149] The Norwegian Healthcare Investigation Board is not responsible for setting healthcare policy, and the Directorate, which is, has not implemented the recommendations, though they have said they are considering them.[148][146][125] Misinformation that Norway had banned gender affirming care proliferated on social media.[146]

Misinformation, by the way, that you continue to peddle in.

[Manuel_D]

https://share.google/OfLzb9jqQywV1ZxOt

> While European health authorities aren’t instituting bans on treatment, currently minors in six European countries—Norway, U.K. Sweden, Denmark, France and Finland—can access puberty blockers and cross-sex hormones only if they meet strict eligibility requirements, usually in the context of a tightly controlled research setting. (Italics in the original)

Read through your quotes carefully:

> The Council for Choices in Health Care allows the use of puberty blockers in transgender children after a case-by-case assessment if there are no medical contraindications.

And how many of such cases were granted? This could be a de facto ban, if no such cases are granted.

> issued a non-binding report finding "there is insufficient evidence for the use of puberty blockers and cross sex hormone treatments in young people" and recommending changing to a cautious approach.

Again, how many new patients are being put on blockers after this recommendation?

You're trying to spin this false narrative that patients with gender dysphoria are still being prescribed puberty blockers as normal treatment for GD. This is not the case. Even though the legislatures in these countries haven't banned the treatment, effectively nobody is getting puberty blockers for childhood GD in these countries.

Actions speak louder than words. You can split hairs about how "recommending" the discontinuation of puberty blocks is not ban. But at the end of the day, what unambiguously true is that the vast majority of patients who are prescribed blockers in the US would not be prescribed blockers in these countries. If you have actual stats on the number of new patients prescribed blockers in these countries in 2025, by all means share it.